• Dose- and Time-Dependent Neurotoxicity of Ibotenic Acid in M

  2026-05-12

  This study provides the first systematic, in vivo assessment of ibotenic acid's dose- and time-dependent neurotoxicity in mice, revealing distinct behavioral, biochemical, and neuronal injury markers. The findings establish a refined toxicological framework for modeling neurotoxic mushroom poisoning and inform mechanistic and translational neuroscience research.

• Live-Dead Cell Staining Kit I: Precision in Mammalian Cell V

  2026-05-11

  The Live-Dead Cell Staining Kit I (Calcein AM/PI) from APExBIO delivers rapid, dual-fluorescence discrimination of live and dead mammalian cells—critical for regenerative studies and cytotoxicity assays. Advanced protocol customizations and troubleshooting tips ensure accurate, reproducible results in demanding experimental environments.

• Risedronate Sodium: FPPS Inhibitor for Bone & Cancer Researc

  2026-05-11

  Risedronate Sodium’s unique action as a farnesyl pyrophosphate synthase inhibitor unlocks new precision in osteoclast-mediated bone resorption and antiproliferative assays. Recent advances in nanoparticle and microneedle delivery are overcoming key bioavailability hurdles, enabling next-generation experimental workflows in osteoporosis and cancer research.

• Applied Workflows with EZ Cap EGFP mRNA 5-moUTP for Gene Exp

  2026-05-10

  EZ Cap™ EGFP mRNA (5-moUTP) enables robust, immune-evasive gene expression with superior translation efficiency for in vitro and in vivo studies. Discover actionable workflows, troubleshooting strategies, and the latest innovations that set this enhanced green fluorescent protein mRNA apart in the field of RNA delivery and reporter assays.

• Ibrexafungerp (SKU C8697): Reliable Antifungal Workflows in

  2026-05-09

  This article delivers scenario-driven, evidence-backed guidance for integrating Ibrexafungerp (SKU C8697) into cell-based fungal viability assays and resistant Candida workflows. It contrasts vendor options, addresses protocol design, and highlights reproducibility advantages for biomedical researchers seeking robust, translational antifungal solutions.

• Gap19: Selective Connexin 43 Hemichannel Blocker for Neuropr

  2026-05-09

  Gap19, a selective connexin 43 hemichannel blocker, empowers researchers to dissect neuroglial and immune signaling with high precision. Its unique ability to block ATP release in astrocytes and modulate macrophage polarization makes it indispensable for stroke and neuroinflammation studies.

• Gap26: Transforming Gap Junction Research for Translational

  2026-05-08

  This thought-leadership article unpacks the transformative role of Gap26, a selective connexin 43 mimetic peptide, in advancing translational research. By weaving together deep mechanistic insight, recent experimental advances, and strategic guidance, the article positions Gap26 as an indispensable tool to dissect intercellular signaling—offering a bridge from advanced 3D in vitro models to clinically relevant applications in vascular and neuroprotection research. The discussion is anchored in primary literature and the latest microfluidic osteocyte network models, differentiating this piece from standard product pages through rigorous protocol guidance and a critical outlook on future directions.

• Risedronate Sodium: Advanced Workflows for Bone & Cancer Res

  2026-05-07

  Risedronate Sodium, a potent FPP synthase inhibitor, is redefining experimental design in bone metabolism and cancer research. This guide translates the latest nanoformulation breakthroughs and validated protocols into actionable steps—empowering researchers to overcome bioavailability hurdles, optimize assays, and unlock new therapeutic frontiers.

• CHIR-99021 (CT99021): Precision GSK-3 Inhibition in Stem Cel

  2026-05-07

  CHIR-99021 (CT99021) from APExBIO is a highly selective, cell-permeable inhibitor of GSK-3α/β, central to stem cell pluripotency and differentiation workflows. Its robust selectivity and reproducibility underpin reliable modulation of Wnt/β-catenin and TGF-β/Nodal signaling, supporting advanced disease modeling and translational research.

• IEM 1460: Advancing AMPA Receptor Blockade in Neuroprotectio

  2026-05-06

  Explore IEM 1460, a selective AMPA receptor blocker, and its pivotal role in neuroprotection research. This article delivers a deep dive into its mechanism, recent breakthroughs, and practical assay guidance for neuroscience applications.

• Staurosporine: Broad-Spectrum Kinase Inhibitor for Precision

  2026-05-06

  Staurosporine stands as a benchmark broad-spectrum serine/threonine protein kinase inhibitor, empowering cancer researchers with reproducible, high-sensitivity apoptosis induction and kinase pathway dissection. This article explores stepwise workflows, troubleshooting strategies, and translational insights, leveraging APExBIO’s Staurosporine for advanced cell signaling and anti-angiogenesis studies.

• Green Spectrophotometric Quantification of Alfuzosin HCl in

  2026-05-05

  Alqahtani et al. (2024) introduce the first validated green spectrophotometric methods—absorbance subtraction and ratio difference—for simultaneous quantification of Alfuzosin HCl and tadalafil in binary mixtures. Their approach addresses spectral overlap, offering accurate, affordable, and straightforward quantification for benign prostatic hyperplasia (BPH) combination therapies.

• One-step TUNEL Cy5 Apoptosis Detection Kit: Applied Workflow

  2026-05-05

  The One-step TUNEL Cy5 Apoptosis Detection Kit empowers researchers to visualize and quantify apoptotic DNA fragmentation with high sensitivity across both tissue and cell-based models. Its Cy5-based fluorescence is ideal for complex, multiplexed studies—streamlining apoptosis detection in translational research and facilitating troubleshooting in challenging contexts.

• Risedronate Sodium: Advanced Delivery and Mechanisms in Bone

  2026-05-04

  Explore the multifaceted applications of Risedronate Sodium, a potent FPP synthase inhibitor, with a focus on breakthrough delivery systems and mechanistic insights driving bone metabolism and osteoporosis research.

• Icatibant for Severe Viral Infections: Evidence, Mechanism,

  2026-05-04

  The reference letter presents clinical experiences and early trial data on the use of icatibant, a bradykinin B2 receptor antagonist, in severe viral infections including hantavirus-induced nephropathia epidemica and COVID-19 pneumonia. It highlights the mechanistic rationale for targeting the kinin–kallikrein system, discusses observed outcomes, and recommends further investigation for high-mortality hantavirus syndromes.

499 records 15/34 page Previous Next First page 上5页 1112131415 下5页 Last page